{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:27:34Z","timestamp":1790440054011,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ackdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1053\/j.ackd.2014.08.003","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T03:09:15Z","timestamp":1424401755000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Aldosterone Blockade in CKD: Emphasis on Pharmacology"],"prefix":"10.1053","volume":"22","author":[{"given":"Michael H.","family":"Schwenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib1","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"issue":"1 Pt 2","key":"10.1053\/j.ackd.2014.08.003_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib5","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1291\/hypres.27.303","article-title":"Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status","volume":"27","author":"Sato","year":"2004","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10741-005-2346-0","article-title":"Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation","volume":"10","author":"Joffe","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"12","key":"10.1053\/j.ackd.2014.08.003_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/cvr\/28.12.1863","article-title":"Aldosterone and cardiac fibrosis: in\u00a0vitro studies","volume":"28","author":"Fullerton","year":"1994","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10.1053\/j.ackd.2014.08.003_bib10","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"issue":"1 Pt 2","key":"10.1053\/j.ackd.2014.08.003_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.ackd.2014.08.003_bib13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ki.1978.114","article-title":"Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure","volume":"14","author":"Berl","year":"1978","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hen\u00e9","year":"1982","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ackd.2014.08.003_bib16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/archinte.1986.00360230061010","article-title":"Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction","volume":"146","author":"Reams","year":"1986","journal-title":"Arch Intern Med"},{"issue":"1-3","key":"10.1053\/j.ackd.2014.08.003_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000334161","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"33","author":"Bomback","year":"2012","journal-title":"Blood Purif"},{"issue":"3-4","key":"10.1053\/j.ackd.2014.08.003_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/07435809809032689","article-title":"Aldosterone in obesity","volume":"24","author":"Goodfriend","year":"1998","journal-title":"Endocr Res"},{"issue":"2","key":"10.1053\/j.ackd.2014.08.003_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000209744","article-title":"Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review","volume":"30","author":"Bomback","year":"2009","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2014.08.003_bib20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ajh.2012.47","article-title":"Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment","volume":"25","author":"Sarzani","year":"2012","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1470320309352353","article-title":"Disordered aldosterone-volume relationship in end-stage kidney disease","volume":"10","author":"Bomback","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2014.08.003_bib23","doi-asserted-by":"crossref","first-page":"e57511","DOI":"10.1371\/journal.pone.0057511","article-title":"Aldosterone and mortality in hemodialysis patients: role of volume overload","volume":"8","author":"Hung","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11906-011-0202-2","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"13","author":"Volk","year":"2011","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000167016","article-title":"Extracellular volume and aldosterone interaction in chronic kidney disease","volume":"27","author":"Klemmer","year":"2009","journal-title":"Blood Purif"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2010.46","volume":"33","author":"Ando","year":"2010","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib28","doi-asserted-by":"crossref","first-page":"F1402","DOI":"10.1152\/ajprenal.00691.2010","article-title":"Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats","volume":"300","author":"Kawarazaki","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1681\/ASN.2011070734","article-title":"Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation","volume":"23","author":"Kawarazaki","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2014.08.003_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/hr.2009.86","article-title":"Mineralocorticoid receptor activation in obesity hypertension","volume":"32","author":"Nagase","year":"2009","journal-title":"Hypertens Res"},{"issue":"8","key":"10.1053\/j.ackd.2014.08.003_bib31","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1053\/j.ackd.2014.08.003_bib32","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/MNH.0b013e3283312fc8","article-title":"Benefits of dietary sodium restriction in the management of chronic kidney disease","volume":"18","author":"Krikken","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib36","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II\u2013renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"10.1053\/j.ackd.2014.08.003_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"issue":"11","key":"10.1053\/j.ackd.2014.08.003_bib38","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"issue":"7","key":"10.1053\/j.ackd.2014.08.003_bib39","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1470320311417272","article-title":"Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy","volume":"13","author":"Persson","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","article-title":"Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy","volume":"6","author":"Bomback","year":"2012","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2014.08.003_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2014.08.003_bib45","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib46","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2014.08.003_bib47","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/j.ajkd.2009.11.006","article-title":"Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases","volume":"55","author":"Bianchi","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib51","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9149(02)02580-8","article-title":"Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade","volume":"90","author":"Blaustein","year":"2002","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2014.08.003_bib54","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5414\/CN106973","article-title":"Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study","volume":"76","author":"Shavit","year":"2011","journal-title":"Clin Nephrol"},{"issue":"20","key":"10.1053\/j.ackd.2014.08.003_bib57","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"9 Pt 1","key":"10.1053\/j.ackd.2014.08.003_bib59","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1053\/j.ackd.2014.08.003_bib60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000100106","article-title":"Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis","volume":"27","author":"Steigerwalt","year":"2007","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib61","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib62","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"2","key":"10.1053\/j.ackd.2014.08.003_bib63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/18.2.318","article-title":"Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis","volume":"18","author":"Fukuta","year":"2003","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib64","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/HJH.0b013e32835f955c","article-title":"Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients","volume":"31","author":"Flevari","year":"2013","journal-title":"J Hypertens"},{"issue":"3","key":"10.1053\/j.ackd.2014.08.003_bib65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-9343(03)00293-6","article-title":"Aldosterone blockade and vascular calcification in hemodialysis patients","volume":"115","author":"Nitta","year":"2003","journal-title":"Am J Med"},{"issue":"8","key":"10.1053\/j.ackd.2014.08.003_bib66","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2014.08.003_bib67","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?","volume":"33","author":"Chua","year":"2010","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1345\/aph.1R011","article-title":"Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis","volume":"46","author":"Baker","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/157340212804546134","article-title":"Mineralocorticoid receptor-associated hypertension and target organ damage: clinical relevance for resistant hypertension in end stage renal disease","volume":"8","author":"Rekhtman","year":"2012","journal-title":"Curr Hypertens Rev"},{"issue":"11","key":"10.1053\/j.ackd.2014.08.003_bib70","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/17.11.2035","article-title":"Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function","volume":"17","author":"Hausmann","year":"2002","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000210553","article-title":"Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients","volume":"114","author":"Matsumoto","year":"2009","journal-title":"Cardiology"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib72","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/DMDI.1987.5.4.273","article-title":"The metabolism and biopharmaceutics of spironolactone in man","volume":"5","author":"Overdiek","year":"1987","journal-title":"Rev Drug Metab Drug Interact"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/clpt.1986.219","article-title":"Influence of food on the bioavailability of spironolactone","volume":"40","author":"Overdiek","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1053\/j.ackd.2014.08.003_bib75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1053\/j.ackd.2014.08.003_bib76","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1053\/j.ackd.2014.08.003_bib77","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment","volume":"45","author":"Ravis","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"10","key":"10.1053\/j.ackd.2014.08.003_bib79","first-page":"1331","article-title":"Safety, tolerability, and pharmacokinetics of eplerenone, a selective aldosterone blocker","volume":"22","author":"Tolbert","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1053\/j.ackd.2014.08.003_bib80","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1592\/phco.24.8.750.36076","article-title":"Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure","volume":"24","author":"Cavallari","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ackd.2014.08.003_bib81","first-page":"200","article-title":"Racial differences in potassium response to spironolactone in heart failure","volume":"12","author":"Cavallari","year":"2006","journal-title":"CHF"},{"issue":"7","key":"10.1053\/j.ackd.2014.08.003_bib82","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1053\/j.ackd.2014.08.003_bib83","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2014.08.003_bib84","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","article-title":"Race influences the safety and efficacy of spironolactone in severe heart failure","volume":"6","author":"Vardeny","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1053\/j.ackd.2014.08.003_bib85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.amjcard.2007.02.097","article-title":"Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure","volume":"100","author":"Biolo","year":"2007","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1053\/j.ackd.2014.08.003_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.30.1.1","article-title":"Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure","volume":"30","author":"Cavallari","year":"2010","journal-title":"Pharmacotherapy"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514001232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514001232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T03:16:59Z","timestamp":1566357419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559514001232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1548559514001232"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2014.08.003","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone Blockade in CKD: Emphasis on Pharmacology","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}